In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Selected Start-Ups Founded in 2000 (1/00)

Executive Summary

{In Vivo} summarizes the technologies of several medical companies founded within the last year. [Camitro Corp.] is developing computational models to predict ADME/PK properties of drug candidates. Researchers will be able to search for and purchase chemical compounds through [ChemNavigator.com]. Launched in September 1999, [Imetrx Inc.] is a cardiovascular interventional device company focused on locating and characterizing unstable coronary plaques that are responsible for atherosclerosis and acute cardiovascular events. Denmark's [NsGene A/S] is a joint venture of NeuroSearch A/S and the University of Lund. [Protein Pathways Inc.] aims to improve the speed and focus of drug development by determining functions for all genome-encoded proteins. [Trek Diagnostics Systems Inc.], a microbiology diagnostics testing company, was founded in January 1999 with the acquisition of the AccuMed International Inc.'s microbiology division.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel